Inhibiting drug efflux transporters improves efficacy of ALS therapeutics

Research identified promising therapeutics in cell models of Amyotrophic Lateral Sclerosis (ALS), but there is limited progress translating effective treatments to animal models and patients, and ALS remains a disease with no effective treatment. One explanation stems from an acquired pharmacoresistance driven by the drug efflux transporters P‐glycoprotein (P‐gp) and breast cancer‐resistant protein (BCRP), which we have shown are selectively upregulated at the blood‐brain and spinal cord barrier (BBB/BSCB) in ALS mice and patients. Pharmacoresistance is well appreciated in other brain diseases, but overlooked in ALS despite many failures in clinical trials.

• Publication year

  2014

• Venue

  Annals of Clinical and Translational Neurology

• Publication date

  2014-11-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/acn3.141PMID 25574474PMCID 4284125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyotrophic lateral sclerosis: Problems and prospects

  2013cited by this paper
• The changing scene of amyotrophic lateral sclerosis

  2013cited by this paper
• Enhancing Mitochondrial Calcium Buffering Capacity Reduces Aggregation of Misfolded SOD1 and Motor Neuron Cell Death without Extending Survival in Mouse Models of Inherited Amyotrophic Lateral Sclerosis

  2013cited by this paper
• Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport.

  2012cited by this paper
• Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.

  2012cited by this paper
• Impaired blood-brain/spinal cord barrier in ALS patients.

  2012cited by this paper
• Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis

  2012cited by this paper
• Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

  2011cited by this paper
• Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice

  2011influential reference
• Reduction of Circulating Endothelial Cells in Peripheral Blood of ALS Patients

  2010cited by this paper
• Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

  2010cited by this paper
• Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET

  2010cited by this paper
• Interactions between riluzole and ABCG2/BCRP transporter.

  2009cited by this paper
• Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat.

  2009cited by this paper
• Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice

  2009cited by this paper
• Progress in Brain Penetration Evaluation in Drug Discovery and Development

  2008cited by this paper
• Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain.

  2008cited by this paper
• ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration

  2008cited by this paper
• Design, power, and interpretation of studies in the standard murine model of ALS

  2008cited by this paper
• Progress in Brain Penetration Evaluation in Drug Discovery and Development

  2008cited by this paper
• Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS.

  2007cited by this paper
• Minocycline and riluzole brain disposition: interactions with p‐glycoprotein at the blood–brain barrier

  2007cited by this paper
• Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy

  2007cited by this paper
• A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

  2007cited by this paper
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cited by this paper
• P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution

  2007cited by this paper
• The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.

  2006cited by this paper
• Neuroprotective agents for clinical trials in ALS: systematic assessment.

  2006cited by this paper
• Neuroprotective agents for clinical trials in ALS: a systematic assessment.

  2006cited by this paper
• Complete Dissociation of Motor Neuron Death from Motor Dysfunction by Bax Deletion in a Mouse Model of ALS

  2006cited by this paper
• Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

  2004cited by this paper
• Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

  2004cited by this paper
• Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase

  2003cited by this paper
• Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis

  2003cited by this paper
• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  2002cited by this paper
• Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis

  1998cited by this paper
• Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis

  1997cited by this paper
• Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis

  1996cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper

• A Modeling Investigation of the CYP1A Drug Interactions of Riluzole

  2025cites this paper
• Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs

  2025cites this paper
• Brain distribution study of [14C]-Riluzole following intranasal administration in mice.

  2025cites this paper
• Entering the era of precision medicine to treat amyotrophic lateral sclerosis

  2025cites this paper
• A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery

  2024influential citation
• HDAC6 inhibition as a mechanism to prevent neurodegeneration in the mSOD1G93A mouse model of ALS

  2024cites this paper
• The impact of ATP-binding cassette transporters in the diseased brain: Context matters

  2024cites this paper
• Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  2024cites this paper
• Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

  2024cites this paper
• Sex-Dependent Changes to the Intestinal and Hepatic Abundance of Drug Transporters and Metabolizing Enzymes in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

  2024cites this paper
• A patient-derived amyotrophic lateral sclerosis blood-brain barrier cell model reveals focused ultrasound-mediated anti-TDP-43 antibody delivery

  2024influential citation
• Assessing the Effect of Riluzole on Motor Unit Discharge Properties

  2024cites this paper
• Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice.

  2024cites this paper
• Emerging Targets in Amyotrophic lateral sclerosis (ALS): The Promise of ATP-Binding Cassette (ABC) transporter Modulation.

  2024cites this paper
• Brain-Gut-Microbiota Axis in Amyotrophic Lateral Sclerosis: A Historical Overview and Future Directions

  2023cites this paper
• Overview of current melanoma therapies

  2023cites this paper
• HDAC6 inhibition as a mechanism to prevent axon degeneration in the mSOD1G93A mouse model of ALS

  2023cites this paper
• Concentric Tube Robot for Intrathecal Drug Administration

  2023cites this paper
• MR-guided focused ultrasound-induced blood-brain barrier opening for brain metastasis: a review.

  2023cites this paper
• In vitro identification of decreased function phenotype ABCG2 variants.

  2023cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis

  2022cites this paper
• Vascular endothelial cells: a fundamental approach for brain waste clearance.

  2022cites this paper
• Regulation of P-Glycoprotein in the Brain

  2022cites this paper
• Multifunctional nanomedicine strategies to manage brain diseases

  2022cites this paper
• Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis

  2022cites this paper
• A Comprehensive Review of Cross-Linked Gels as Vehicles for Drug Delivery to Treat Central Nervous System Disorders

  2022cites this paper
• Harmine and 7,8-dihydroxyflavone synergistically suitable for amyotrophic lateral sclerosis management: An in silico study

  2022cites this paper
• Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.

  2022cites this paper
• P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

  2022cites this paper
• Brain Drug Delivery and Neurodegenerative Diseases: Polymeric PLGA-Based Nanoparticles as a Forefront Platform.

  2022cites this paper
• A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

  2022cites this paper
• Neuroimmune Crosstalk Between the Peripheral and the Central Immune System in Amyotrophic Lateral Sclerosis

  2022cites this paper
• NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone

  2022cites this paper
• The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

  2021cites this paper
• Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

  2021cites this paper
• Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level

  2021cites this paper
• Phytotherapeutics: The Rising Role of Drug Transporters in Herb-Drug Interactions with Botanical Supplements

  2021cites this paper
• Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

  2021cites this paper
• Emerging Nano-Carrier Strategies for Brain Tumor Drug Delivery and Considerations for Clinical Translation

  2021cites this paper
• Expressional Study of Permeability Glycoprotein and Multidrug Resistance Protein 1 in Drug-resistant Mesial Temporal Lobe Epilepsy

  2021cites this paper
• Title: Expressional Study of Permeability glycoprotein (P-gp) and Multidrug Resistance Protein 1 (MRP-1) in Drug-Resistant Mesial Temporal Lobe Epilepsy Running Title: Drug-resistance in mesial temporal lobe epilepsy

  2021cites this paper
• Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

  2021cites this paper
• Altered blood–brain barrier and blood–spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety

  2021influential citation
• PET Imaging of ABC Transporters at the Blood-Brain Barrier

  2020cites this paper
• Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders.

  2020cites this paper
• Applications of focused ultrasound in the brain: from thermoablation to drug delivery

  2020cites this paper
• The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

  2020cites this paper
• Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery.

  2020cites this paper
• Bidens pilosa Extract Administered after Symptom Onset Attenuates Glial Activation, Improves Motor Performance, and Prolongs Survival in a Mouse Model of Amyotrophic Lateral Sclerosis

  2020cites this paper
• Identification of Small Molecule Enhancers of Immunotherapy for Melanoma

  2020cites this paper
• P-glycoprotein Expression Is Upregulated in a Pre-Clinical Model of Traumatic Brain Injury

  2020cites this paper
• Neurological diseases at the blood-brain barrier: Stemming new scientific paradigms using patient-derived induced pluripotent cells.

  2020cites this paper
• Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.

  2019cites this paper
• Long Non-coding RNA KCNQ1OT1 Contributes to Antiepileptic Drug Resistance Through the miR-138-5p/ABCB1 Axis in vitro

  2019cites this paper
• 3D brain angiogenesis model to reconstitute functional human blood–brain barrier in vitro

  2019cites this paper
• Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases

  2019cites this paper
• Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.

  2019cites this paper
• P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice

  2019cites this paper
• Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients

  2019influential citation
• Contributions of Drug Transporters to Blood-Brain Barriers.

  2019cites this paper
• Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis

  2019cites this paper
• First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound

  2019cites this paper
• Tumor biological characteristics of Vestibular Schwannoma

  2019cites this paper
• Neurotheranostics as personalized medicines.

  2019cites this paper
• A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

  2018cites this paper
• Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology

  2018cites this paper
• Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody

  2018cites this paper
• Impaired tissue barriers as potential therapeutic targets for Parkinson’s disease and amyotrophic lateral sclerosis

  2018cites this paper
• Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies

  2017cites this paper
• Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

  2017cites this paper
• DOK7 gene therapy enhances motor activity and life span in ALS model mice

  2017cites this paper
• Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies

  2017cites this paper
• BCRP expression in schwannoma, plexiform neurofibroma and MPNST

  2017cites this paper
• Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.

  2017cites this paper
• Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.

  2017cites this paper
• Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood–brain barrier

  2017cites this paper
• CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.

  2016cites this paper
• Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P‐Glycoprotein) in endothelial cells of the blood–brain barrier in mutant superoxide dismutase 1‐linked amyotrophic lateral sclerosis

  2016cites this paper
• Effect of Disease Pathologies on Transporter Expression and Function

  2016cites this paper
• Transporters as Drug Targets in Neurological Diseases

  2016cites this paper
• Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases

  2016cites this paper
• Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier

  2016cites this paper
• Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.

  2015cites this paper
• A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies

  2015cites this paper
• Chronic inhibitory effect of riluzole on trophic factor production.

  2015cites this paper
• Amyotrophic Lateral Sclerosis: mechanism behind mutant SOD toxicity and improving current therapeutic strategies

  2014cites this paper